Ocular Therapeutix, Inc. Completes Series D Financing To Support Phase II Sustained Drug Delivery Clinical Trials
Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.